1st Feb 2021 12:04
e-Therapeutics PLC - Oxford-based drug discovery platform - Says it recently filed a patent application related to the chemistry of novel GalNAc-conjugated siRNAs, an important element of its RNAi platform that enables specific hepatocyte targeting for liver gene silencing.
Says a number of siRNA constructs have been designed with "potentially beneficial safety and potency profiles" and additional patent applications are expected to be filed shortly.
"We believe that the new patent applications, combined with our know-how, will provide a significant competitive advantage in RNAi," says e-Therapeutics. "The new constructs will include features to minimise potential microRNA off-target effects, thermally destabilising regions of the siRNA for reduced toxicity and important position-specific stabilisation chemistries to improve potency."
Multiple experiments are underway to test these constructs.
Current stock price: 19.80 pence
Year-to-date change: up 13%
By Lucy Heming;Â [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ETX.L